Effect of glycine on insulin secretion and action in healthy first-degree relatives of type 2 diabetes mellitus patients.
The aim of this study was to identify the effect of glycine on insulin secretion and action in healthy first-degree relatives of Type 2 diabetes mellitus patients. A randomized, double-blind, placebo-controlled clinical trial was performed in 12 healthy, non-obese volunteers who were first-degree relatives of Type 2 diabetes mellitus patients. Six volunteers received a morning dose of glycine 5 g orally and the other six received placebo. At baseline without drugs and after pharmacological intervention, a metabolic profile and, to assess insulin secretion and action, a hyperglycemic-hyperinsulinemic clamp study were performed. There were no significant differences in baseline metabolic profile, insulin secretion or action between groups. Changes from baseline of early (p < 0.05), late (p < 0.05), and total insulin (p < 0.02) responses were higher in the glycine group than in controls. There were no significant differences in the changes from baseline of insulin action between groups. In conclusion, a morning dose of glycine 5 g orally increased early, late and total insulin responses without changes in insulin action in healthy first-degree relatives of Type 2 diabetes mellitus patients.
González-Ortiz
M
M
Medical Research Unit in Clinical Epidemiology, West National Medical Center, Mexican Institute of Social Security, Guadalajara. uiec@prodigy.net.mx
Medina-Santillán
R
R
Martínez-Abundis
E
E
von Drateln
C R
CR
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003924:Diabetes Mellitus, Type 2; D005192:Family Health; D005260:Female; D005998:Glycine / Q000008:administration & dosage*; D006801:Humans; D007328:Insulin / Q000097:blood* / Q000378:metabolism*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D008297:Male; D012016:Reference Values
D007328:Insulin; D005998:Glycine